Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
The discovery of activating mutations in the epidermal growth factor receptor (<i>EGFR</i>) gene and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). <i>EGFR</i> mutation-positive NS...
Saved in:
Main Authors: | Yukari Tsubata, Ryosuke Tanino, Takeshi Isobe |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/5cfa5435b6c34b2f8549d7967e087ca1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018) -
Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin
by: AVILA,ANA D, et al.
Published: (2007) -
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017) -
Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
by: Ling-Ling Kong, et al.
Published: (2017)